We read the article by Leal et al. with interest about a 17-year-old male
with Kearns–Sayre syndrome (KSS), diagnosed upon the clinical presentation,
instrumental findings and the muscle biopsy findings [1]. Despite some peculiarities of the phenotype, the presentation at onset was
mild and the further course uneventful. We have the following comments and concerns.The main disadvantage of this case report is that the diagnosis was not genetically
confirmed. Since phenotypic features of mitochondrial disorders (MIDs) may overlap in
various syndromic MIDs, it is not reliable to diagnose KSS only upon the clinical
manifestations and muscle biopsy findings. This is of particular importance since a few
cases of KSS were reported which did not carry a single mtDNA deletion but a mtDNA point
mutation such as the mutation m.3243A>G [2] or m.3249G>A [3]. There are
also KSSpatients due to a single mtDNA duplication.Rarely, KSSpatients may present with epilepsy. Did the presented patient ever undergo EEG
recordings? Was paroxysmal activity recorded indicative of mitochondrial epilepsy? Was ever
any type of seizure observed in the presented patient?Rarely, KSSpatients may develop embolic stroke, resulting from intracardiac thrombi. Even
more rarely, stroke-like episodes, the phenotypic hallmark of mitochondrial encephalopathy,
lactic acidosis, and stroke-like episode syndrome, have been reported in KSS. Was cerebral
MRI indicative of a previous ischemic stroke or a metabolic stroke manifesting with a
stroke-like lesion?It would also be helpful to know more about the neurological findings in the presented
patient. Were tendon reflexed preserved or diminished; was there wasting or muscle weakness;
were there fasciculations, fatigue or exercise intolerance; and was the gag reflex preserved
or abolished? Was there any indication for dystonia as has been described in some KSSpatients?We should also be informed about the findings on cerebral imaging since KSSpatients may
manifest with cerebral involvement including intellectual decline, dystonia, epilepsy or
encephalopathy.Rarely, KSSpatients may develop dilated cardiomyopathy. Thus, it is important that KSSpatients undergo regular echocardiographic investigations and regular clinical cardiologic
examination. Cardiomyopathy is usually accessibly to cardiac therapy, why adequate treatment
may improve a patient's condition significantly.Repeatedly, sudden cardiac death has been reported in KSS. Concerning the indication for
implanting an implantable cardioverter defibrillator (ICD), KSSpatients should undergo
regular Holter monitoring not to overlook ventricular arrhythmias. The indication for
implantation of an ICD should follow the current guidelines.Some KSSpatients with corneal endothelial dysfunction have been reported. Did the patient
ever complain about corneal problems? Did ophthalmologic investigations ever detect corneal
involvement in the underlying metabolic defect?KSS may also go along with hypogonadism. Were hormone levels determined and was pituitary
insufficiency excluded?Finally, there is some confusion concerning the course of symptoms [1]. The authors mention that the patient was first seen by them at a
‘regular ophthalmic and general health check’ [1]. At the same time, they mention that the patient was not seen by
a physician since the last 5 years [1]. When
were ptosis, ophthalmoplegia, and double vision first recognized? In the discussion, they
mention that the patient was diagnosed with chronic porgressive external ophthalmoplegia at
the age of 21 years, but in the case description, KSS was diagnosed at the age of 17 years.
These contradictory statements require clarification.Overall, this interesting case presentation could be improved by genetic studies, more
extensive work-up for potential multisystem disease and by regular follow-up investigations,
particularly cardiologic investigations. Additionally, some inconsistencies require
clarification.
Authors: E Wilichowski; G C Korenke; W Ruitenbeek; L De Meirleir; A Hagendorff; A J Janssen; W Lissens; F Hanefeld Journal: J Neurol Sci Date: 1998-05-07 Impact factor: 3.181